SORC-13 is under clinical development by Soricimed Biopharma and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect SORC-13’s likelihood of approval (LoA) and phase transition for Epithelial Ovarian Cancer took place on 26 Dec 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their SORC-13 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

SORC-13 overview

SORC-13 is under development for treatment of advanced refractory solid tumors such as epithelial ovarian cancer, colon cancer, non-small cell lung cancer, breast cancer, peritoneal cancer, esophageal cancer, uterine cancer, gastrointestinal stromal tumor, prostate cancer, parotid cancer, head and neck cancer, nasopharyngeal cancer, adenoid cystic cancer and pancreatic ductal adenocarcinoma and also for Coronavirus Disease 2019 (COVID-19). The drug candidate is administered as an intravenous infusion. It comprises of a bi-functional parent peptide called soricidin obtained from the shrew venom. The drug candidate targets TRPV6 ion channel.

Soricimed Biopharma overview

Soricimed Biopharma formerly BioProspecting NB, operates as a drug and diagnostic developer that offers pain management solutions. The company offers services such as development and commercialization of therapeutic and diagnostic programs. Its oncology management platform arises from the ability of soricidin and the C-series peptides to modulate the activity of a calcium ion channel. Soricimed Biopharma’s products are used in the treatment of breast cancer, ovarian cancer, and prostate cancer, and other cancer types. The company operates through a network of contract research organizations that provide research outside its core capacities. Soricimed Biopharma is headquartered in Moncton, New Brunswick, Canada.

Quick View SORC-13 LOA Data

Report Segments
  • Innovator
Drug Name
  • SORC-13
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Infectious Disease
  • Oncology
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.